Cargando…

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.

Our previous experimental studies have shown that the best approach to increase the biological anti-tumour activity of interleukin 2 (IL-2) is not co-administration of another cytokine, but the association with immunomodulating neurohormones, in an attempt to reproduce the physiological links betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Lissoni, P., Barni, S., Tancini, G., Ardizzoia, A., Ricci, G., Aldeghi, R., Brivio, F., Tisi, E., Rovelli, F., Rescaldani, R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968792/
https://www.ncbi.nlm.nih.gov/pubmed/8286206
_version_ 1782134818019999744
author Lissoni, P.
Barni, S.
Tancini, G.
Ardizzoia, A.
Ricci, G.
Aldeghi, R.
Brivio, F.
Tisi, E.
Rovelli, F.
Rescaldani, R.
author_facet Lissoni, P.
Barni, S.
Tancini, G.
Ardizzoia, A.
Ricci, G.
Aldeghi, R.
Brivio, F.
Tisi, E.
Rovelli, F.
Rescaldani, R.
author_sort Lissoni, P.
collection PubMed
description Our previous experimental studies have shown that the best approach to increase the biological anti-tumour activity of interleukin 2 (IL-2) is not co-administration of another cytokine, but the association with immunomodulating neurohormones, in an attempt to reproduce the physiological links between psychoendocrine and immune systems, which play a fundamental role in the regulation of the immune responses. In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone. To confirm these preliminary results, a clinical trial was performed in locally advanced or metastatic patients with solid tumours other than renal cell cancer and melanoma. The study included 80 consecutive patients, who were randomised to be treated with IL-2 alone subcutaneously (3 million IU day-1 at 8.00 p.m. 6 days a week for 4 weeks) or IL-2 plus MLT (40 mg day-1 orally at 8.00 p.m. every day starting 7 days before IL-2). A complete response was obtained in 3/41 patients treated with IL-2 plus MLT and in none of the patients receiving IL-2 alone. A partial response was achieved in 8/41 patients treated with IL-2 plus MLT and in only 1/39 patients treated with IL-2 alone. Tumour objective regression rate was significantly higher in patients treated with IL-2 and MLT than in those receiving IL-2 alone (11/41 vs 1/39, P < 0.001). The survival at 1 year was significantly higher in patients treated with IL-2 and MLT than in the IL-2 group (19/41 vs 6/39, P < 0.05). Finally, the mean increase in lymphocyte and eosinophil number was significantly higher in the IL-2 plus MLT group than in patients treated with IL-2 alone; on the contrary, the mean increase in the specific marker of macrophage activation neopterin was significantly higher in patients treated with IL-2 alone. The treatment was well tolerated in both groups of patients. This study shows that the concomitant administration of the pineal hormone MLT may increase the efficacy of low-dose IL-2 subcutaneous therapy.
format Text
id pubmed-1968792
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19687922009-09-10 A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Lissoni, P. Barni, S. Tancini, G. Ardizzoia, A. Ricci, G. Aldeghi, R. Brivio, F. Tisi, E. Rovelli, F. Rescaldani, R. Br J Cancer Research Article Our previous experimental studies have shown that the best approach to increase the biological anti-tumour activity of interleukin 2 (IL-2) is not co-administration of another cytokine, but the association with immunomodulating neurohormones, in an attempt to reproduce the physiological links between psychoendocrine and immune systems, which play a fundamental role in the regulation of the immune responses. In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone. To confirm these preliminary results, a clinical trial was performed in locally advanced or metastatic patients with solid tumours other than renal cell cancer and melanoma. The study included 80 consecutive patients, who were randomised to be treated with IL-2 alone subcutaneously (3 million IU day-1 at 8.00 p.m. 6 days a week for 4 weeks) or IL-2 plus MLT (40 mg day-1 orally at 8.00 p.m. every day starting 7 days before IL-2). A complete response was obtained in 3/41 patients treated with IL-2 plus MLT and in none of the patients receiving IL-2 alone. A partial response was achieved in 8/41 patients treated with IL-2 plus MLT and in only 1/39 patients treated with IL-2 alone. Tumour objective regression rate was significantly higher in patients treated with IL-2 and MLT than in those receiving IL-2 alone (11/41 vs 1/39, P < 0.001). The survival at 1 year was significantly higher in patients treated with IL-2 and MLT than in the IL-2 group (19/41 vs 6/39, P < 0.05). Finally, the mean increase in lymphocyte and eosinophil number was significantly higher in the IL-2 plus MLT group than in patients treated with IL-2 alone; on the contrary, the mean increase in the specific marker of macrophage activation neopterin was significantly higher in patients treated with IL-2 alone. The treatment was well tolerated in both groups of patients. This study shows that the concomitant administration of the pineal hormone MLT may increase the efficacy of low-dose IL-2 subcutaneous therapy. Nature Publishing Group 1994-01 /pmc/articles/PMC1968792/ /pubmed/8286206 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Lissoni, P.
Barni, S.
Tancini, G.
Ardizzoia, A.
Ricci, G.
Aldeghi, R.
Brivio, F.
Tisi, E.
Rovelli, F.
Rescaldani, R.
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
title A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
title_full A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
title_fullStr A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
title_full_unstemmed A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
title_short A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
title_sort randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968792/
https://www.ncbi.nlm.nih.gov/pubmed/8286206
work_keys_str_mv AT lissonip arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT barnis arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT tancinig arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT ardizzoiaa arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT riccig arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT aldeghir arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT briviof arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT tisie arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT rovellif arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT rescaldanir arandomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT lissonip randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT barnis randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT tancinig randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT ardizzoiaa randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT riccig randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT aldeghir randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT briviof randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT tisie randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT rovellif randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma
AT rescaldanir randomisedstudywithsubcutaneouslowdoseinterleukin2alonevsinterleukin2plusthepinealneurohormonemelatonininadvancedsolidneoplasmsotherthanrenalcancerandmelanoma